Beacon Biosignals
Beacon Biosignals develops an EEG neurobiomarker platform to accelerate clinical trials and enable new treatments for neurological and psychiatric diseases. The company utilizes advanced machine learning and a comprehensive Clinico-EEG database to provide quantitative assessments, optimize patient cohorts, and enhance treatment efficacy.
Company Overview
Beacon Biosignals specializes in accelerating clinical trials and enabling new treatments for neurological and psychiatric diseases. The company's EEG neurobiomarker platform offers quantitative assessments of treatment impacts on EEG and sleep data, ensuring clinical endpoints are met. By understanding PK/PD relationships with brain activity, Beacon Biosignals helps identify doses with optimal efficacy and safety profiles, supporting further development and regulatory success.
Products and Technology
Beacon Biosignals offers the Dreem Headband, an FDA 510(k) cleared product used for scalable sleep monitoring in clinical trials. The company's platform includes an end-to-end augmented EEG system, leveraging state-of-the-art machine learning and a Clinico-EEG database. The Datastore™ captures quantitative EEG endpoints and includes clinical-grade EEG data from thousands of individuals, facilitating the discovery of disease-specific neurobiomarkers.
Services and Solutions
Beacon Biosignals provides advanced EEG analytics and at-home brain monitoring for various stages of clinical studies. Their services include target engagement demonstration, dose selection guidance, and development of quantitative endpoints to enhance the probability of trial success. The company also offers cloud-based EEG viewer support for clinician workflows and network of epileptologists who provide central EEG reading services augmented by AI for efficiency and standardization.
Partnerships and Collaborations
Beacon Biosignals collaborates with biopharma companies, academic medical centers, and neurotechnology developers. These partnerships aim to improve the diagnosis and treatment of neurological and psychiatric diseases by utilizing cutting-edge machine learning algorithms and scalable solutions for data acquisition. The company empowers academic partners to expand the impact of their EEG research, thereby advancing therapeutic development in neurology, psychiatry, and sleep medicine.
Sector Focus
Beacon Biosignals operates primarily in the fields of neurology, psychiatry, sleep, and immunology. The company uses advanced EEG analytics to enhance understanding of treatment efficacy and guide label expansion for new therapeutic applications. They develop and validate neurobiomarkers, helping to improve cohort selection, de-confound standard clinical assessments, and identify novel endpoints that support the development of therapies for neurological and psychiatric conditions.